RDGLClinical Trials•globenewswire•
Investigational Device Exemption (IDE) Application for Human Clinical Trials at Mayo Declined By FDA
Sentiment:Negative (-70)
Summary
Kennewick, WA, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL) Following the 30-day review period, the FDA declined approval of the Radiogel® IDE submission.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on August 14, 2025 by globenewswire